Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Jo Raskin"'
Autor:
Mégane Willems, Arnaud Scherpereel, Eric Wasielewski, Jo Raskin, Hélène Brossel, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Majeed Jamakhani, Vincent Heinen, Renaud Louis, Bernard Duysinx, Malik Hamaidia, Luc Willems
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundOnly a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the majority, the condition will irremediably relapse after 13 to 18 months. In this study, we hypothesized that patients’
Externí odkaz:
https://doaj.org/article/b0aa66a4104343c0ad35e8ad8b16efe7
Publikováno v:
European Respiratory Review, Vol 30, Iss 161 (2021)
Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment remained relatively unchanged, with chemotherapy remaining the cornerstone
Externí odkaz:
https://doaj.org/article/5cb253c0cadf4b3bbef1ed03bbf1c828
Autor:
Sophie Rovers, Annelies Janssens, Jo Raskin, Patrick Pauwels, Jan P. van Meerbeeck, Evelien Smits, Elly Marcq
Publikováno v:
Biomedicines, Vol 10, Iss 3, p 673 (2022)
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that
Externí odkaz:
https://doaj.org/article/2ab04385e8c04a289f2f60a2e8573ba3
Publikováno v:
Journal of the Belgian Society of Radiology, Vol 104, Iss 1 (2020)
This article details a correction to the article: De Bondt C, Snoeckx A, Raskin J. A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer pati
Externí odkaz:
https://doaj.org/article/66234f68af134dc4923926d1991f4f12
Publikováno v:
Journal of the Belgian Society of Radiology, Vol 104, Iss 1 (2020)
We report the case of a 72-year-old female never-smoker with stage IV endothelial growth factor receptor (EGFR) mutated lung adenocarcinoma. This patient was started on first line tyrosine kinase inhibitor (TKI) and seemingly developed new bone metas
Externí odkaz:
https://doaj.org/article/1edad655291d4e118b38514c433ead92
Autor:
Elien Augustus, Kaat Van Casteren, Laure Sorber, Peter van Dam, Geert Roeyen, Marc Peeters, Alex Vorsters, An Wouters, Jo Raskin, Christian Rolfo, Karen Zwaenepoel, Patrick Pauwels
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231058 (2020)
Although liquid biopsies offer many advantages over tissue biopsies, they are not yet standard practice. An important reason for the lack of implementation is the unavailability of well standardized techniques and guidelines, especially for pre-analy
Externí odkaz:
https://doaj.org/article/a91766e399ec43e68b52608935c34cd3
Publikováno v:
ERJ Open Research, Vol 4, Iss 1 (2018)
There is growing awareness of the need for advance care planning in patients with chronic obstructive pulmonary disease (COPD). However, do-not-resuscitate (DNR) order implementation remains a challenge in clinical practice. We retrospectively analys
Externí odkaz:
https://doaj.org/article/4a4105a816b04110bd7670a8233591e5
Autor:
Paul K. Paik, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Karin Berghoff, Elif Sikoglu, John Heymach, Christian Britschgi, Maya Gottfried, Melissa Johnson, Frank Griesinger, Keunchil Park, Christine M. Bestvina, Jyoti D. Patel, Yuh-Min Chen, James Chih-Hsin Yang, Hye Ryun Kim, Byoung Chul Cho, Wade T. Iams, Michael Thomas, Egbert F. Smit, Julien Mazieres, Santiago Viteri, Alexis B. Cortot, Jo Raskin, Marina Chiara Garassino, Remi Veillon, Enriqueta Felip, Hiroshi Sakai, Xiuning Le
Purpose:Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non–small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups.Patients and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5552ad5b36a619d7db55e5782ec1e34c
https://doi.org/10.1158/1078-0432.c.6531026.v1
https://doi.org/10.1158/1078-0432.c.6531026.v1
Autor:
Paul K. Paik, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Karin Berghoff, Elif Sikoglu, John Heymach, Christian Britschgi, Maya Gottfried, Melissa Johnson, Frank Griesinger, Keunchil Park, Christine M. Bestvina, Jyoti D. Patel, Yuh-Min Chen, James Chih-Hsin Yang, Hye Ryun Kim, Byoung Chul Cho, Wade T. Iams, Michael Thomas, Egbert F. Smit, Julien Mazieres, Santiago Viteri, Alexis B. Cortot, Jo Raskin, Marina Chiara Garassino, Remi Veillon, Enriqueta Felip, Hiroshi Sakai, Xiuning Le
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019d486fdfd847164e30262bd47deff8
https://doi.org/10.1158/1078-0432.22482902.v1
https://doi.org/10.1158/1078-0432.22482902.v1
Autor:
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
Publikováno v:
Future Oncology. 18:1039-1054
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c5b96a113868d2d819fcd3ed9a4f3a
https://doi.org/10.2217/fon-2021-1406
https://doi.org/10.2217/fon-2021-1406